Southwest Synthetic Pharmaceutical To Consolidate Founder Group’s Pharmaceutical Business
This article was originally published in PharmAsia News
Southwest Synthetic Pharmaceutical has announced plans to issue additional shares to Peking University International Hospital to acquire the latter's subsidiary Chongqing Daxin Pharmaceutical. Southwest Synthetic and Peking University International Hospital are both subsidiaries of China's IT giant Founder Group. Sources disclose that the conglomerate will transfer its 87.65 percent stake in Daxin Pharmaceutical to Southwest Synthetic, such that all of its pharmaceutical assets are consolidated within one entity. Founder's strategy is to develop IT, pharmaceutical and health care as its main core businesses. (Click here for more - Chinese Language)
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.